Development and validation of a rabbit model of Pseudomonas aeruginosa non-ventilated pneumonia for preclinical drug development

Keyphrases

• Rabbit Model 100%
• Pneumonia 100%
• Pseudomonas Aeruginosa (P. aeruginosa) 100%
• Preclinical Development 100%
• Tobramycin 80%
• Lung 60%
• Clearance Rate 60%
• Cmax 40%
• Clinical Efficacy 40%
• Dosing Regimen 40%
• Humanized 40%
• Antibacterial Drugs 40%
• New Antibacterials 40%
• Clinical Trials 20%
• Dose Effect 20%
• Kidney 20%
• Natural History 20%
• Antibiotics 20%
• Validation Studies 20%
• Disease Progression 20%
• Drug Target 20%
• Spleen 20%
• Respiratory Failure 20%
• Respiratory Death 20%
• Concentration-dependent 20%
• Post-infection 20%
• Severe Neutropenia 20%
• New Drugs 20%
• Multidrug-resistant Pathogens 20%
• Preclinical Animal Models 20%
• Acute Respiratory Distress Syndrome 20%
• Pulmonary Edema 20%
• Hyperlactatemia 20%
• Acute Lung Inflammation 20%
• Ventilator-associated Pneumonia 20%
• Meropenem 20%
• PaO2 20%
• Thrombocytopenia 20%
• Community-acquired Pneumonia 20%
• Severe Hypoglycemia 20%
• Animal History 20%
• Endobronchial 20%
• Human Pathophysiology 20%
• Animal Disease 20%
• Severe Hypoxemia 20%
• Pseudomonas Aeruginosa Pneumonia 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Drug Development 100%
• Pseudomonas aeruginosa 100%
• Rabbit Model 100%
• Tobramycin 80%
• Antiinfective Agent 60%
• Leporidae 60%
• Infection 40%
• Hypoglycemia 20%
• Neutropenia 20%
• Clinical Trial 20%
• Pathophysiology 20%
• Infectious Agent 20%
• Disease Exacerbation 20%
• Drug Delivery System 20%
• Hypoxemia 20%
• Antibiotics 20%
• Adult Respiratory Distress Syndrome 20%
• Lung Edema 20%
• Respiratory Failure 20%
• Ventilator Associated Pneumonia 20%
• Meropenem 20%
• Hyperlactatemia 20%
• Thrombocytopenia 20%
• Hospital Acquired Pneumonia 20%